Get the Stockscreener App
0.26
15.00%
-0.0459
After Hours:
.26
Nkgen Biotech Inc stock is traded at $0.26, with a volume of 64,430.
It is down -15.00% in the last 24 hours and down -15.00% over the past month.
See More
Previous Close:
$0.3059
Open:
$0.26
24h Volume:
64,430
Relative Volume:
7.63
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-15.00%
1M Performance:
-15.00%
6M Performance:
-75.69%
1Y Performance:
-92.59%
1-Day Range:
$0.26
$0.28
1-Week Range:
$0.26
$0.28
52-Week Range:
$0.26
$0.345
Nkgen Biotech Inc Stock (NKGN) Company Profile
Compare NKGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.26 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkgen Biotech Inc Stock (NKGN) Latest News
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire
NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Nasdaq
Delisting of Securities from The Nasdaq Stock Market - Yahoo Finance
NKGen Biotech (NYSE:NKGN) Stock Price Down 0.2% – What’s Next? - Defense World
NKGen administers first dose of NK cell therapy to Alzheimer’s patient By Investing.com - Investing.com South Africa
NKGen administers first dose of NK cell therapy to Alzheimer’s patient - Investing.com
NKGen Biotech Administers First Dose of Troculeucel to - GlobeNewswire
Breakthrough: New NK Cell Treatment Offers Hope for Alzheimer's Patients Who Failed Standard Therapy - Stock Titan
Revolutionary NK Cell Therapy for Alzheimer's Expands Clinical Trial to International Sites - Stock Titan
NKGNW SEC FilingsNKGen Biotech 10-K, 10-Q, 8-K Forms - Stock Titan
Nkgen biotech sees $2.5 million stock purchase by major shareholder - Investing.com Canada
NKGen Biotech Enters Stock Purchase Agreement - TipRanks
NKGen Biotech Delays Quarterly Report Filing - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally - GlobeNewswire
NKGen Biotech’s Strategic Stock Purchase Agreement - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations - Stock Titan
NKGen Biotech to Present Phase 1 Clinical Data on Troculeucel for Alzheimer's Disease at ASGCT Annual Meeting - Nasdaq
NKGen Biotech to Present Troculeucel Clinical and Biomarker - GlobeNewswire
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Stock Titan
Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World
NKGen Biotech secures amended loan terms with East West Bank By Investing.com - Investing.com India
NKGen Biotech secures amended loan terms with East West Bank - Investing.com
NKGen Biotech (NYSE:NKGN) Trading Up 4.3% – Here’s What Happened - Defense World
NKGen Biotech To Present on the Use of Troculeucel for - GlobeNewswire
Breakthrough NK Cell Therapy Data Reveals New Hope for Alzheimer's Patients - Stock Titan
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial - GlobeNewswire
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) - Yahoo
Breakthrough: NK Cell Therapy Reverses Moderate Alzheimer's to Mild in Clinical Trial - Stock Titan
NKGen Biotech Delays Annual Report Filing - TipRanks
3 Stocks Near 52-Week Lows With Strong Rebound Potential - The Globe and Mail
NKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 Conference - Nasdaq
NKGen Biotech To Present Updated Troculeucel Data at the - GlobeNewswire
Groundbreaking NK Cell Therapy Data for Alzheimer's: 6-Month Results to be Revealed at Major Conference - Stock Titan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
NKGen Biotech To Present on Potential of Troculeucel for - GlobeNewswire
NKGen Biotech to Present Troculeucel as Potential Neurodegenerative Disease Therapy at Alzheimer’s & Parkinson’s Drug Development Summit - Nasdaq
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit - GlobeNewswire
Revolutionary NK Cell Therapy Advances Against Alzheimer's: FDA Fast-Tracks Promising Treatment - StockTitan
NKGen Biotech secures $5 million convertible loan By Investing.com - Investing.com South Africa
NKGen Biotech secures $5 million convertible loan - Investing.com India
4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal
NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split - TipRanks
NKGen Biotech shifts to OTC Markets after Nasdaq delisting By Investing.com - Investing.com South Africa
NKGen Biotech shifts to OTC Markets after Nasdaq delisting - Investing.com India
NKGen Biotech, Inc. to Transition from the Nasdaq Global - GlobeNewswire
NKGen Biotech Delisted: What Happens to Its FDA Fast-Tracked Alzheimer's Program Now? - StockTitan
NKGen Biotech, Inc. SEC 10-Q Report - TradingView
Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - The Manila Times
NKGen Biotech announces administration of first dose of troculeucel - TipRanks
Nkgen Biotech Inc Stock (NKGN) Financials Data
There is no financial data for Nkgen Biotech Inc (NKGN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.40%
2.49%
Cap:
|
Volume (24h):